Reports Q1 EUR118.1M vs. EUR182.8M last year. “In the Q1, we made substantial progress in executing towards our oncology strategy, highlighted by data presentations from our priority pan-tumor program pumitamig as well as our versatile antibody-drug conjugate portfolio. Simultaneously, we continue to broaden our clinical programs to include novel-novel combinations in order to inform the optimal set-up for registrational combination trials and maximize the potential of our pipeline,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech (BNTX). “We will continue to focus on accelerating our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients living with cancer.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline
- BioNTech, HPE, BitMine, US Bancorp, Rezolve AI Shock
- Summit partner selection for ASCO plenary signals strong OS, says Leerink
- BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch
- BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer